A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice

• DOI: 10.1101/2022.03.02.482616
• Publication Date: 2022-03-03T04:05:24Z
• Authors: Vijayendra Dasari; Kirrilee Beckett; Shane Horsefield; George Ambalathingal; Rajiv Khanna
• Keywords: 0301 basic medicine; Immunity, Cellular; 0303 health sciences; QH301-705.5; Epitopes, T-Lymphocyte; RC581-607; CD8-Positive T-Lymphocytes; Antibodies, Viral; Immunity, Humoral; 3. Good health; Mice; 03 medical and health sciences; Adjuvants, Immunologic; Oligodeoxyribonucleotides; Toll-Like Receptor 9; Cytomegalovirus Infections; Vaccines, Subunit; Animals; Humans; Vaccines, Combined; Immunologic diseases. Allergy; Biology (General); Research Article

AbstractThere is now convincing evidence that the successful development of an effective CMV vaccine will require improved formulation and adjuvant selection that is capable of inducing both humoral and cellular immune responses. Here, we have designed a novel bivalent subunit vaccine formulation based on CMV-encoded oligomeric glycoprotein B (gB) and polyepitope protein in combination with human compatible TLR9 agonist CpG1018. The polyepitope protein includes multiple minimal HLA class I-restricted CD8+ T cell epitopes from different antigens of CMV. This subunit vaccine generated durable anti-viral antibodies, CMV-specific CD4+ and CD8+ T cell responses in multiple HLA expressing mice. Antibody responses included broad TH1 isotypes (IgG2a, IgG2b and IgG3) and potently neutralized CMV infection in fibroblasts and epithelial cells. Furthermore, polyfunctional antigen-specific T cell immunity and antiviral antibody responses showed long-term memory maintenance. These observations argue that this novel vaccine strategy, if applied to humans, could facilitate the generation of robust humoral and cellular immune responses which may be more effective in preventing CMV-associated complications in various clinical settings.